<DOC>
	<DOC>NCT02934568</DOC>
	<brief_summary>This study is to allow continued use of ribociclib (LEE011) as single agent or in combination with other investigational treatments in patients benefitting from treatment in an eligible Novartis-sponsored ribociclib (LEE011) study that has reached its primary objective(s) or has been halted for other reasons.</brief_summary>
	<brief_title>Ribociclib (LEE011) Rollover Study for Continued Access</brief_title>
	<detailed_description />
	<criteria>1. Patient is currently enrolled in an eligible Novartissponsored study and receiving ribociclib (LEE011) as single agent or in combination with other investigational treatment. 2. Patient is currently deriving clinical benefit from the study treatment, as determined by the investigator. 1. Patient has been permanently discontinued from ribociclib (LEE011) in the parent protocol for any reason. 2. Patients who do not meet parent protocol criteria to continue study treatment.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Ribociclib</keyword>
	<keyword>LEE011</keyword>
</DOC>